These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
436 related articles for article (PubMed ID: 23685782)
1. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells. Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782 [TBL] [Abstract][Full Text] [Related]
2. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227 [TBL] [Abstract][Full Text] [Related]
3. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960 [TBL] [Abstract][Full Text] [Related]
4. The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent. Cheng Y; Borcherding N; Ogunsakin A; Lemke-Miltner CD; Gibson-Corley KN; Rajan A; Choi AB; Wongpattaraworakul W; Chan CHF; Salem AK; Weiner GJ; Simons AL Sci Rep; 2021 Jan; 11(1):1535. PubMed ID: 33452311 [TBL] [Abstract][Full Text] [Related]
5. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Lu H; Dietsch GN; Matthews MA; Yang Y; Ghanekar S; Inokuma M; Suni M; Maino VC; Henderson KE; Howbert JJ; Disis ML; Hershberg RM Clin Cancer Res; 2012 Jan; 18(2):499-509. PubMed ID: 22128302 [TBL] [Abstract][Full Text] [Related]
6. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866 [TBL] [Abstract][Full Text] [Related]
7. Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity. Dietsch GN; Lu H; Yang Y; Morishima C; Chow LQ; Disis ML; Hershberg RM PLoS One; 2016; 11(2):e0148764. PubMed ID: 26928328 [TBL] [Abstract][Full Text] [Related]
8. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines. Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052 [TBL] [Abstract][Full Text] [Related]
9. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. López-Albaitero A; Lee SC; Morgan S; Grandis JR; Gooding WE; Ferrone S; Ferris RL Cancer Immunol Immunother; 2009 Nov; 58(11):1853-64. PubMed ID: 19319529 [TBL] [Abstract][Full Text] [Related]
10. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR Ming Lim C; Stephenson R; Salazar AM; Ferris RL Oncoimmunology; 2013 Jun; 2(6):e24677. PubMed ID: 23894722 [TBL] [Abstract][Full Text] [Related]
11. The 30-kDa and 38-kDa antigens from Mycobacterium tuberculosis induce partial maturation of human dendritic cells shifting CD4(+) T cell responses towards IL-4 production. Heuer M; Behlich AS; Lee JS; Ribechini E; Jo EK; Lutz MB BMC Immunol; 2013 Oct; 14():48. PubMed ID: 24089996 [TBL] [Abstract][Full Text] [Related]
12. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid. Kumai T; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Kobayashi H Head Neck; 2016 Mar; 38(3):410-6. PubMed ID: 25352398 [TBL] [Abstract][Full Text] [Related]
13. Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells. Friedman J; Padget M; Lee J; Schlom J; Hodge J; Allen C Oral Oncol; 2019 Mar; 90():38-44. PubMed ID: 30846174 [TBL] [Abstract][Full Text] [Related]
14. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients. Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441 [TBL] [Abstract][Full Text] [Related]
16. An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck. Pinette A; McMichael E; Courtney NB; Duggan M; Benner BN; Choueiry F; Yu L; Abood D; Mace TA; Carson WE Cancer Immunol Immunother; 2019 Aug; 68(8):1379-1389. PubMed ID: 31338557 [TBL] [Abstract][Full Text] [Related]
18. Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status. Baysal H; De Pauw I; Zaryouh H; De Waele J; Peeters M; Pauwels P; Vermorken JB; Smits E; Lardon F; Jacobs J; Wouters A Br J Cancer; 2020 Sep; 123(5):752-761. PubMed ID: 32541873 [TBL] [Abstract][Full Text] [Related]
19. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409 [TBL] [Abstract][Full Text] [Related]
20. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Bier H; Hoffmann T; Haas I; van Lierop A Cancer Immunol Immunother; 1998 May; 46(3):167-73. PubMed ID: 9625540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]